TGF-β / Smad Signaling
The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
-
B5946 EW-71971 CitationTarget: BMP and Other Activin ReceptorsSummary: Selective inhibitor of TGF-β type I receptor kinase
-
B5965 Tamoxifen1 CitationTarget: PKCSummary: TGF-β modulatory and PKC inhibitory effects
-
A3771 RKI-1447Target: ROCKSummary: Potent ROCK1/ROCK2 inhibitor
-
A3133 A 83-01Summary: ALK-5 inhibitor
-
B2191 Dequalinium ChlorideTarget: PKC|Calcium-Activated Potassium (KCa) ChannelsSummary: anti-tumor agent and PKC inhibitor
-
B2287 LY3649471 CitationSummary: inhibitor of TGF-β type I receptor kinase domain
-
A8464 LY21097614 CitationSummary: TβRI/II kinase inhibitor
-
A8525 Sotrastaurin (AEB071)Target: PKCSummary: PKC inhibitor
-
A2600 (-)-Epigallocatechin gallate (EGCG)Target: BACESummary: Antioxidant, antiangiogenic and antitumor agent
-
B1404 DCC-2036 (Rebastinib)Target: FLT3|Bcr-Abl|Tie-2|KDRSummary: Bcr-Abl inhibitor